热门资讯> 正文

默克收购维罗纳制药公司获得法院批准

2025-10-07 04:46

Merck's (NYSE:MRK) ~$10B acquisition of Verona Pharma (NASDAQ:VRNA) has been granted approval by the High Court of Justice of England and Wales.
Under terms, MSD, the trade name of Merck outside the US and Canada, will acquire Verona Pharma for $107 per American Depository Share, with each one accounting for eight Verona ordinary shares.
The deal closing is effective Oct. 7. Verona shares will no longer be traded as of market close Monday.

More on Merck

Merck: A Race Against The Keytruda Clock
Merck: Initiating "Strong Buy" On Shift To Qlex SC Injection For Solid Tumors
Merck: Game-Changing Oncology Drugs Power Stock Surge
HHS ramps up drug pricing efforts with another proposed rule sent for review
Trump holding off on pharma tariffs to negotiate more deals - report

推荐文章

风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。